Tirzepatide may deliver bigger weight loss but greater lean-mass loss vs semaglutide, study suggests
TL;DR Summary
A new study suggests Lilly’s tirzepatide yields more weight loss than Novo Nordisk’s semaglutide, but may also cause greater loss of lean body mass, indicating a potential trade-off in body composition.
- Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests Endpoints News
- Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds Reuters
- Novo obesity drug outperforms Lilly’s in preserving lean body mass: study Seeking Alpha
- Real-World Evidence Confirms Oral Semaglutide's Metabolic Potency Medical Dialogues
- Tirzepatide linked to more lean mass loss than semaglutide European Medical Journal
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
0 min
vs 1 min read
Condensed
64%
85 → 31 words
Want the full story? Read the original article
Read on Endpoints News